Aulos bioscience raises $20 million in series a extension financing from apple tree partners

Larkspur, calif.--(business wire)--aulos bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class il-2 therapeutics, today announced $20 million in series a extension funding committed by apple tree partners (atp). the funds will be used to advance aulos' lead human monoclonal antibody candidate, au-007, through its initial phase 2 clinical study in solid tumor cancers. “we are very pleased to strengthen this partnership wi.
AAPL Ratings Summary
AAPL Quant Ranking